Predictive Value of Microdose Pharmacokinetics Merel van NulandHilde RosingJos H. Beijnen Review Article 27 April 2019 Pages: 1221 - 1236
Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update Elise J. SmoldersAnouk M. E. JansenDavid M. Burger Review Article Open access 21 May 2019 Pages: 1237 - 1263
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review Wonkyung ByonSamira GaronzikCharles E. Frost Review Article Open access 14 May 2019 Pages: 1265 - 1279
Physicochemical Properties, Biotransformation, and Transport Pathways of Established and Newly Approved Medications: A Systematic Review of the Top 200 Most Prescribed Drugs vs. the FDA-Approved Drugs Between 2005 and 2016 Anitha SaravanakumarArmin SadighiFatemeh Akhlaghi Systematic Review 10 April 2019 Pages: 1281 - 1294
Population Pharmacokinetics/Pharmacodynamics of Ticagrelor in Children with Sickle Cell Disease Carl AmilonMohammad NiaziBengt Hamrén Original Research Article 11 April 2019 Pages: 1295 - 1307
Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I–III Clinical Trials Ahmed A. SuleimanMukul MinochaAhmed A. Othman Original Research Article Open access 04 May 2019 Pages: 1309 - 1321
Optimizing Estimated Glomerular Filtration Rate to Support Adult to Pediatric Pharmacokinetic Bridging Studies in Patients with Cystic Fibrosis Ryan L. CrassManjunath P. Pai Original Research Article 10 April 2019 Pages: 1323 - 1332
A Prospective Clinical Study Characterizing the Influence of Morbid Obesity on the Pharmacokinetics of Gentamicin: Towards Individualized Dosing in Obese Patients Cornelis SmitRoeland E. WasmannCatherijne A. J. Knibbe Original Research Article Open access 24 April 2019 Pages: 1333 - 1343
Assessment of Antiepileptic Drug Concentrations in HIV-Infected versus HIV-Negative Patients: A Retrospective Analysis Dario CattaneoSara BaldelliCristina Gervasoni Short Communication 04 April 2019 Pages: 1345 - 1350
Comment on: “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?” Philippe LechatJacques RopersStephane Mouly Letter to the Editor 27 August 2019 Pages: 1351 - 1352
Authors’ Reply to Lechat et al.: “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?” Didier ConcordetPeggy GandiaPierre-Louis Toutain Letter to the Editor Open access 27 August 2019 Pages: 1353 - 1354
